Abstract: This invention relates generally to the field of nucleic acid analysis. In particular, the invention provides a method for typing a target gene, using, inter alia, a chip comprising a support suitable for use in nucleic acid hybridization having immobilized thereon an oligonucleotide probe complementary to said target nucleotide sequence and at least one of the following oligonucleotide control probes: a positive control probe, a negative control probe, a hybridization control probe and an immobilization control probe. Oligonucleotide probes or probes arrays for typing a HLA target gene are also provided.

Abstract: The invention relates to the identification and selection of novel biomarkers and the identification and selection of novel biomarker combinations which are differentially expressed in individuals with mild osteoarthritis as compared with individuals without osteoarthritis. Polynucleotides and proteins which specifically and/or selectively hybridize to the products of the biomarkers of the invention are also encompassed within the scope of the invention as are kits containing said polynucleotides and proteins for use in diagnosing mild osteoarthritis. Further encompassed by the invention is the use of the polynucleotides and proteins which specifically and/or selectively hybridize to the product of the biomarkers of the invention to monitor disease regression in an individual and to monitor the efficacy of therapeutic regimens. The invention also provides for methods of using the products of the biomarkers of the invention in the identification of novel therapeutic targets for osteoarthritis.

Abstract: Methods of detecting nucleic acids, including methods of detecting two or more nucleic acids in multiplex branched-chain DNA assays, are provided. Nucleic acids captured on a solid support are detected, for example, through cooperative hybridization events that result in specific association of a label with the nucleic acids. Compositions, kits, and systems related to the methods are also described.

Abstract: The present invention provides an efficient way for high throughput haplotype analysis. Several polymorphic nucleic acid markers, such as SNPs, can be simultaneously and reliably determined through multiplex PCR of single nucleic acid molecules in several parallel single molecule dilutions and the consequent statistical analysis of the results from these parallel single molecule multiplex PCR reactions results in reliable determination of haplotypes present in the subject. The nucleic acid markers can be of any distance to each other on the chromosome. In addition, an approach wherein overlapping DNA markers are analyzed can be used to link smaller haplotypes into larger haplotypes. Consequently, the invention provides a powerful new tool for diagnostic haplotyping and identifying novel haplotypes.

Abstract: A method of manufacturing a DNA (deoxyribonucleic acid) chip is provided. The DNA chip has a plurality of transistors formed on a substrate and an organic layer and a DNA probe sequentially stacked on a gate of the transistor. The method includes forming an inter-layer insulation layer on the substrate to cover the transistors, planarizing the inter-layer insulation layer, forming at least two contact holes exposing gate electrodes of the transistors in the inter-layer insulation layer, selectively forming organic layers on the exposed gate electrodes, attaching a first DFR (dry film resist) layer to the upper surface of the inter-layer insulation layer to cover the contact holes, removing a portion of the first DFR layer covering a first contact hole among the contact holes, attaching a first DNA probe to the organic layers in the first contact hole, and removing a remaining portion of the first DFR layer.

Abstract: The present invention provides methods for diagnosing mental disorders (e.g., psychotic disorders such as schizophrenia and mood disorders such as major depression disorder and bipolar disorder). The invention also provides methods of identifying modulators of such mental disorders as well as methods of using these modulators to treat patients suffering from such mental disorders.

Abstract: Methods are described for determining sulfonator status of a patient and determining dosages of drugs based on copy number of the SULT1A1 gene.

Abstract: Aspects of the present invention provide novel compositions and methods based on novel calpastatin (CAST) genetic markers, such as missense mutations in exon 3 that result in G48D or P52L substitutions (NM_174003.2:c.271G>A and 283C>T), a G/T substitution in intron 3 (AAFC02060381.1:g.2110G>T) and a GAAA repeat in intron 8 (AAFC02060381.1:g.6700[(GAAA)4]+[(GAAA)5]. Particular aspects provide novel markers for fertility (e.g., daughter pregnancy rate, DPR) and longevity (e.g., productive life, PL) in, for example, dairy cattle. Additional aspects provide for novel methods comprising marker-assisted selection to improve fertility and/or longevity in dairy cattle. Therefore, in particular embodiments, a combination of genetic selection based on one or more of the novel CAST markers, and high PTA potentials of milk production traits, provides for improved reproductive traits in association with continued high milk production traits.

Abstract: This document relates to methods and materials involved in detecting tissue rejection (e.g., organ rejection). For example, this document relates to methods and materials involved in the early detection of kidney tissue rejection.

Abstract: The present invention provides methods of screening chickens to determine those more likely to have a lean or fat phenotype. The invention also provides methods of screening chickens to identify a polymorphism associated with a fat or lean phenotype.

Abstract: The present invention provides a method for assessment of the Microsatellite Instability (MSI) status of medically relevant conditions associated with MSI phenotype such as e.g. neoplastic lesions. The method is based on the analysis of a monomorphic T25 (CAT25) mononucleotide repeat located in the 3?-UTR of the Caspase 2 (CASP2) gene. Based on the determination of the length of the named mononucleotide repeat the presence or absence of MSI may be assessed. Determination of the length is performed in a single PCR procedure. Alternatively an enhanced assessment could be performed by combining the CAT25 marker with further markers such as BAT25 and BAT26 in a single multiplex PCR process.

Abstract: Methods for identifying expression of markers indicative of the presence of esophageal, a squamous cell cancer, a squamous cell cancer of the head and neck, colon cancer and melanoma are provided. Also provided are articles of manufacture useful in such methods and compositions containing primers and probes useful in such methods.

Abstract: Aspects of the present invention also provide methods based on novel UCN3 nucleotide polymorphisms selected from the group consisting of AAFC03043460.1:g.8272-8281AATAATAAAT(SEQ ID NO: 9)>GGAGC, g.8208C>T, g.8265C>T, g.8287T>C, g.8412A>G, g.8426T>A, c.8786C>T, g.9074T>C, c.12609C>T, c.12621T>C, c.12667T>G and c.12669C>A , which may provide novel markers for marbling and/or subcutaneous fat. Additional aspects provide for novel methods which may comprise marker-assisted selection or marker-assisted management to improve marbling and/or subcutaneous fat depth in cattle.

Abstract: The method of diagnosing lesions of crystalline lens such as cataract is disclosed. It comprises detecting variation of crygs gene, transcript and/or protein of individuals compared with normalty. The individual suffers from cataract more possible than normalty when occurring the variation. The present invention also discloses the method and pharmaceutical composition of treating lesions of crystalline lens such as cataract.

Abstract: This invention relates to transgenic winter oilseed rape (WOSR) plants, plant material and seeds, harboring a specific transformation event. It pertains to winter oilseed rape plants, more particularly to a pair of winter oilseed rape plants, which is particularly suited for the production of hybrid seed. More specifically, one plant is characterized by being male-sterile, due to the presence in its genome of a male sterility gene, while the other is characterized by carrying a fertility-restorer gene, capable of preventing the activity of the male-sterility gene. The invention further provides a method for producing hybrid seed, a process for producing a transgenic WOSR plant oil or plant, and a method to identify a transgenic plant, cell or tissue. A kit for identifying the transgenic plants comparing the elite event of the present invention is also described.

Abstract: A method for identifying a nucleotide polymorphism, the method comprising hybridizing a labeled oligonucleotide for a wild type or a mutant type to a nucleic acid containing a specific nucleotide polymorphic site in a sample; allowing a nucleic acid-specific label to act thereon; detecting an interaction between the label of the oligonucleotide and the nucleic acid-specific label; and identifying a nucleotide polymorphism, wherein the identification utilizes a difference due to the nucleotide polymorphism in conditions under which the hybridized oligonucleotide is separated into a single strand.

Abstract: The present invention provides methods relating to chemotherapeutic treatment of a cell proliferative disorder. In particular, a method is provided for predicting the clinical response to certain types of chemotherapeutic agents. Alkylating agents, used for the treatment of certain types of tumors including tumors of the nervous system and lymph system, are efficacious agents when the damage they do to tumor cell DNA is not repaired by cellular DNA repair mechanisms. The present invention provides a method for determining the activity of a gene encoding a DNA repair enzyme, thus providing a prediction of the clinical response to alkylating agents.

Abstract: The present invention relates to the identification of a single nucleotide polymorphism (SNP) within the bovine CAST locus encoding the calpastatin protein, wherein the allelic variation of the SNP is a G/C transversion associated with post-mortem muscle tenderness. The invention further relates to oligonucleotides useful in identifying the genotype of bovines as it relates to the CAST locus polymorphic site. The invention also encompasses computer-assisted methods and systems for improving the production efficiency for livestock having marketably tender meat using multiple data, and in particular the genotype of the animals as it relates to the CAST SNP.

Abstract: The early prediction or diagnosis of sepsis advantageously allows for clinical intervention before the disease rapidly progresses beyond initial stages to the more severe stages, such as severe sepsis or septic shock, which are associated with high mortality. Early prediction or diagnosis is accomplished using a molecular diagnostics approach, involving comparing an individual's profile of biomarker expression to profiles obtained from one or more control, or reference, populations, which may include a population who develops sepsis. Recognition of features in the individual's biomarker profile that are characteristic of the onset of sepsis allows a clinician to diagnose the onset of sepsis from a bodily fluid isolated at the individual at a single point in time. The necessity of monitoring the patient over a period of time is, therefore, avoided, advantageously allowing clinical intervention before the onset of serious symptoms.

Abstract: It is intended to provide a means of diagnosing genetic risk of restenosis after coronary angioplasty which shows a high accuracy and a high estimation ratio. The risk of restenosis after coronary angioplasty is diagnosed by a method comprising the following steps: (i) the step of analyzing 2 or more polymorphisms among 6 gene polymorphisms proved as relating to restenosis after balloon expansion or 5 gene polymorphisms proved as relating to restenosis after stent insertion; (ii) the step of determining the genotype of a nucleic acid sample based on the polymorphism data obtained in the above step; and (iii) the step of determining the genetic risk of restenosis after coronary angioplasty form the genotype thus determined.